Advertisement

Topics

Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer

09:15 EST 12 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Peer-reviewed published article shows treatment with axalimogene filolisbac resulted in an overall 12-month survival rate of approximately 35% Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused o...

Other Sources for this Article

Advaxis, Inc.
Noelle Heber, (609) 250-7575
Sr. Director Corporate Communications and Government Affairs
Heber@advaxis.com
or
Media:
Stern Strategy Group
Brian Hyland, (908) 325-3891
Bhyland@sternstrategy.com
or
Rachel Auerbach, (908) 325-3898
Rauerbach@sternstrategy.com
or
Investors:
LHA Investor Relations
Anne Marie Fields, (212) 838-3777
afields@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...